Table 1 Demographics of the unique individuals within the study cohort consisting of Swedish early RA patients diagnosed 1999–2019, treated with MTX in monotherapy as their first prescribed DMARD and with a first-degree relative concordant for early RA and treatment with MTX in DMARD monotherapy; stratification by treatment persistence status
From: Does persistence to methotrexate treatment in early rheumatoid arthritis have a familial component?
MTX persistence at 1 year | MTX persistence at 3 years | |||
|---|---|---|---|---|
Persistent, N = 231 | Non-persistent, N = 116 | Persistent, N = 175 | Non-persistent, N = 172 | |
Female (%) | 159 (69%) | 87 (75%) | 117 (67%) | 129 (75%) |
Seropositive (%) | 169 (75%)a | 86 (75%)b | 126 (74%)a | 129 (75%)b |
Glucocorticoids at baseline (%) | 112 (48%) | 51 (44%) | 80 (46%) | 83 (48%) |
Mean age at the start of MTX (SD) | 60 (14) | 53 (15) | 62 (13) | 53 (15) |
Median year of the start of MTX (Q1–Q3) | 2012 (07–16) | 2011 (06–15) | 2013 (08–16) | 2011 (07–15) |
Median overall number of FDRs identified (Q1–Q3) | 4 (3–5) | 4 (3–5) | 4 (3–5) | 4 (3–5) |
RR (95% CI) | 1.02 (0.87–1.20) | 1.41 (1.14–1.74) | ||
h2 (95% CI) | 0.08 (0*–0.43) | 0.58 (0.27–0.89) | ||